X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (435) 435
male (278) 278
female (268) 268
middle aged (247) 247
cardiac & cardiovascular systems (244) 244
index medicus (232) 232
aged (202) 202
treatment outcome (194) 194
infusions, intravenous (167) 167
abciximab (156) 156
percutaneous coronary intervention (131) 131
platelet aggregation inhibitors - administration & dosage (130) 130
injections, intravenous (124) 124
angioplasty (120) 120
antibodies, monoclonal - administration & dosage (114) 114
immunoglobulin fab fragments - administration & dosage (112) 112
myocardial infarction - therapy (112) 112
angioplasty, balloon, coronary (98) 98
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (98) 98
myocardial infarction - drug therapy (93) 93
fibrinolytic agents - therapeutic use (90) 90
heart attack (90) 90
thrombolytic therapy (89) 89
heart attacks (84) 84
time factors (78) 78
myocardial infarction (77) 77
platelet aggregation inhibitors - therapeutic use (77) 77
cardiology (76) 76
thrombolysis (75) 75
mortality (74) 74
stents (73) 73
adult (72) 72
electrocardiography (69) 69
peripheral vascular disease (69) 69
prospective studies (69) 69
primary angioplasty (68) 68
acute myocardial-infarction (65) 65
cardiac patients (64) 64
fibrinolytic agents - administration & dosage (64) 64
antibodies, monoclonal - therapeutic use (63) 63
coronary angiography (63) 63
immunoglobulin fab fragments - therapeutic use (63) 63
therapy (63) 63
care and treatment (62) 62
stroke (62) 62
trial (60) 60
transluminal angioplasty (58) 58
drug therapy, combination (57) 57
follow-up studies (57) 57
myocardial infarction - mortality (57) 57
reperfusion (57) 57
abridged index medicus (56) 56
drug therapy (56) 56
intravenous bolus abciximab (56) 56
platelet aggregation inhibitors - adverse effects (55) 55
pharmacology & pharmacy (54) 54
risk factors (54) 54
medicine & public health (52) 52
unstable angina (52) 52
anticoagulants - therapeutic use (51) 51
tissue-plasminogen-activator (51) 51
tyrosine - analogs & derivatives (51) 51
cardiovascular (50) 50
anticoagulants - administration & dosage (46) 46
dose-response relationship, drug (46) 46
tissue plasminogen activator - therapeutic use (46) 46
intracoronary (45) 45
eptifibatide (44) 44
tirofiban (44) 44
coronary vessels (43) 43
elevation myocardial-infarction (43) 43
hemorrhage - chemically induced (42) 42
ischemia (42) 42
myocardial infarction - physiopathology (42) 42
thrombosis (42) 42
aged, 80 and over (41) 41
antibodies, monoclonal - adverse effects (41) 41
clinical neurology (41) 41
hematology (41) 41
randomized controlled trials as topic (41) 41
tyrosine - administration & dosage (41) 41
unfractionated heparin (41) 41
combined modality therapy (40) 40
drug administration schedule (40) 40
immunoglobulin fab fragments - adverse effects (40) 40
intravenous thrombolysis (40) 40
peptides - administration & dosage (40) 40
retrospective studies (40) 40
tissue plasminogen activator - administration & dosage (40) 40
acute myocardial infarction (39) 39
clinical trials (39) 39
acute coronary syndromes (38) 38
clopidogrel (38) 38
intervention (38) 38
medicine, general & internal (38) 38
surgery (38) 38
tissue-plasminogen activator (38) 38
analysis (37) 37
randomized-trial (37) 37
angioplasty, balloon, coronary - methods (36) 36
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Lakeridge Health Sciences - Oshawa (1) 1
Mt Sinai Hospital - Stacks (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Withdrawn (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 07/2008, Volume 118, Issue 1, pp. 49 - 57
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9819, pp. 923 - 931
Journal Article
American Heart Journal, ISSN 0002-8703, 2010, Volume 159, Issue 4, pp. 547 - 554
Journal Article
American Heart Journal, ISSN 0002-8703, 2008, Volume 156, Issue 1, pp. 135 - 140
Journal Article
Journal Article
Clinical Research in Cardiology, ISSN 1861-0684, 5/2011, Volume 100, Issue 5, pp. 425 - 432
Administration of abciximab during primary percutaneous coronary intervention (PCI) reduces major adverse cardiac events (MACE) in patients with ST-elevation... 
Myocardial infarction | Abciximab | Medicine & Public Health | Magnetic resonance imaging | Angioplasty | Glycoprotein IIb/IIIa inhibitor | Cardiology | Platelets | Recurrence | Myocardial Infarction - mortality | Injections, Intravenous | Humans | Immunoglobulin Fab Fragments - adverse effects | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Myocardial Infarction - diagnostic imaging | Recovery of Function | Angioplasty, Balloon, Coronary - adverse effects | Myocardial Infarction - therapy | Angioplasty, Balloon, Coronary - mortality | Time Factors | Myocardial Infarction - pathology | Platelet Aggregation Inhibitors - administration & dosage | Female | Myocardial Infarction - physiopathology | Heart Failure - etiology | Heart Failure - mortality | Platelet Aggregation Inhibitors - adverse effects | Risk Assessment | Risk Factors | Ventricular Function, Left - drug effects | Kaplan-Meier Estimate | Myocardium - pathology | Treatment Outcome | Chi-Square Distribution | Coronary Angiography | Disease-Free Survival | Magnetic Resonance Imaging | Immunoglobulin Fab Fragments - administration & dosage | Antibodies, Monoclonal - administration & dosage | Aged | Ventricular Remodeling - drug effects | Germany | Injections, Intra-Arterial | Transluminal angioplasty | Care and treatment | Cardiac patients | Heart attack
Journal Article
Circulation: Cardiovascular Interventions, ISSN 1941-7640, 10/2013, Volume 6, Issue 5, pp. 527 - 534
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 68, Issue 7, pp. 727 - 738
Journal Article
American Heart Journal, ISSN 0002-8703, 2015, Volume 170, Issue 6, pp. 1116 - 1123
Background Thrombus burden and distal embolization are predictive of no-reflow during primary percutaneous coronary intervention (PCI) in patients with acute... 
Cardiovascular | MORTALITY | PERCUTANEOUS CORONARY INTERVENTION | CARDIAC & CARDIOVASCULAR SYSTEMS | NO-REFLOW | OPTICAL COHERENCE TOMOGRAPHY | RATIONALE | PLATELET | REPERFUSION | IMPROVES | INTRAVENOUS BOLUS ABCIXIMAB | THROMBUS-ASPIRATION | Humans | Immunoglobulin Fab Fragments - adverse effects | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Coronary Restenosis - diagnosis | Coronary Angiography - methods | Percutaneous Coronary Intervention - methods | Thrombectomy - methods | No-Reflow Phenomenon - etiology | Female | Thrombosis - therapy | Coronary Restenosis - etiology | Myocardial Infarction - diagnosis | No-Reflow Phenomenon - diagnosis | Postoperative Complications - therapy | Treatment Outcome | Thrombectomy - adverse effects | Tomography, Optical Coherence - methods | Coronary Restenosis - therapy | Myocardial Reperfusion - methods | Postoperative Complications - diagnosis | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Myocardial Infarction - complications | Immunoglobulin Fab Fragments - administration & dosage | Antibodies, Monoclonal - administration & dosage | Thrombosis - etiology | Platelet Aggregation Inhibitors | No-Reflow Phenomenon - therapy | Aged | Percutaneous Coronary Intervention - adverse effects | Thrombosis - diagnosis | Care and treatment | Analysis | Cardiac patients | Heart attack | Tomography | Heart attacks | Angioplasty | Catheters | Blood clots
Journal Article